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Peter Szlosarek3,4, Christian Frezza1,5*† and Eyal Gottlieb1†
Abstract
Background: Loss of function of fumarate hydratase (FH), the mitochondrial tumor suppressor and tricarboxylic
acid (TCA) cycle enzyme, is associated with a highly malignant form of papillary and collecting duct renal cell
cancer. The accumulation of fumarate in these cells has been linked to the tumorigenic process. However, little is
known about the overall effects of the loss of FH on cellular metabolism.
Methods: We performed comprehensive metabolomic analyses of urine from Fh1-deficient mice and stable
isotopologue tracing from human and mouse FH-deficient cell lines to investigate the biochemical signature of the
loss of FH.
Results: The metabolomics analysis revealed that the urea cycle metabolite argininosuccinate is a common
metabolic biomarker of FH deficiency. Argininosuccinate was found to be produced from arginine and fumarate by
the reverse activity of the urea cycle enzyme argininosuccinate lyase (ASL), making these cells auxotrophic for
arginine. Depleting arginine from the growth media by the addition of pegylated arginine deiminase (ADI-PEG 20)
decreased the production of argininosuccinate in FH-deficient cells and reduced cell survival and proliferation.
Conclusions: These results unravel a previously unidentified correlation between fumarate accumulation and the
urea cycle enzyme ASL in FH-deficient cells. The finding that FH-deficient cells become auxotrophic for arginine
opens a new therapeutic perspective for the cure of hereditary leiomyomatosis and renal cell cancer (HLRCC).
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Background
Germline mutations in the tricarboxylic acid (TCA)
cycle enzyme fumarate hydratase (FH, EC 4.2.1.2) lead
to hereditary leiomyomatosis and renal cell cancer
(HLRCC, OMIM #150800), a genetic cancer syndrome
characterized by benign smooth muscle tumors, uterine
fibroids, and a highly malignant form of papillary and
collecting duct renal cell cancer. HLRCC patients carry
heterozygous germline mutations of FH, but loss of het-
erozygosity occurs in the tumors leading to a complete
loss of FH [1]. The tumorigenic process of HLRCC is
characterized by early onset of renal cysts that progress
into malignant carcinoma [2]. Furthermore, reduction of
FH expression is common in renal cancers without FH
germline mutations [3]. Mice with kidney-specific biallelic
deletion of Fh1 develop severe renal cysts. However, these
cysts do not progress into renal carcinoma [4].
It is not yet clear how the loss of FH predisposes pa-
tients to renal cancer. The accumulation of fumarate
was identified as one of the most striking biochemical
features of FH-deficient cells, with a potential tumori-
genic role [5,6]. Indeed, it was initially thought that the
stabilization of the transcription factor hypoxia-inducible
factor (HIF), caused by the accumulation of fumarate,
played a key role in the tumorigenesis of FH-deficient
renal cancer [5-7]. However, the relevance of HIF as a
tumor driver has been recently challenged by the obser-
vation that the genetic ablation of HIF in Fh1-deficient
mice did not abolish cyst formation but, on the contrary,
exacerbated this phenotype [8]. A novel link between
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fumarate accumulation and tumorigenesis was later
proposed; fumarate was found to covalently modify
cysteine residues of Keap1, the negative regulator of
the transcription factor Nrf2, suggesting a role for a
deregulated antioxidant response in the formation of FH-
deficient tumors [8,9].
While the mechanisms of tumorigenesis in FH-deficient
cells have been extensively investigated, the metabolic
changes caused by the loss of FH activity have only been
partially addressed. By using Fh1-deficient mouse epithe-
lial kidney cells we have recently shown that in the ab-
sence of Fh1, the TCA cycle is truncated causing an
accumulation of fumarate and succinate paralleled by a
decrease of malate and citrate. The accumulation of TCA
cycle metabolites in Fh1−/− cells diverts TCA metabolites
into heme biosynthesis and degradation, engaging a linear
metabolic pathway beginning with glutamine uptake and
ending with bilirubin excretion [10]. Of note, one of the
key enzymes of this pathway, heme oxygenase-1, is an
Nrf2 target gene, underscoring the role of an activated
antioxidant response in the survival of FH-deficient
cells [11]. An additional metabolic adaptation was
identified in human FH-deficient cells. It was demon-
strated that, by reversing parts of the TCA cycle, the re-
ductive carboxylation of alpha-ketoglutarate (AKG) to
isocitrate can generate citrate and malate from glutamine,
thus providing anabolic building blocks required for cell
proliferation [12].
The loss of FH is expected to have broader effects on
cellular metabolism. Metabolomic analyses are now es-
sential tools to investigate cell metabolism which have
been recently exploited to identify cancer-specific meta-
bolic pathways, such as serine metabolism [13,14] and
reductive carboxylation of glutamine-derived AKG
[12,15]. Further to providing important insights into
cellular metabolism, metabolomic investigation of body
fluids, such as urine and blood, may be an invalua-
ble tool for finding novel cancer-specific metabolic
biomarkers. In this work, we performed metabolomic in-
vestigations of urine from Fh1-deficient mice and of
growth media of FH-deficient cell lines. We identified a
distinct metabolic signature, marked by the abundant se-
cretion of fumarate and the urea cycle metabolite
argininosuccinate. Furthermore, we demonstrated that
argininosuccinate is produced from arginine and fumar-
ate by the reversed activity of the urea cycle enzyme
argininosuccinate lyase (ASL, EC 4.3.2.1). Finally, by
using an arginine-depleting enzyme with US Food
and Drug Administration (FDA) orphan drug status,
pegylated arginine deiminase (ADI-PEG 20) [16], we
demonstrated that blocking the conversion of arginine
to argininosuccinate specifically reduces cell proliferation of
FH-deficient cells, opening new opportunities for the
treatment of FH-deficient renal cell cancer.
Methods
Animal work
All work was performed in accordance with the Animals
(Scientific Procedures) Act 1986.
Cell culture
Fh1fl/fl, Fh1−/−, UOK262 and UOKpFH cell lines were
obtained and cultured as previously described [10]. In brief,
all cell lines were cultured in DMEM supplemented with
10% FBS and 2 mM glutamine. The mouse cell line was
additionally supplemented with 1 mM pyruvate and 50 μg/
mL uridine.
Ultrasound
High resolution ultrasound imaging of mouse kidneys
was performed as previously described [17], using a Vevo
770 system (Visual Sonics, Toronto, Canada) with a
25 MHz transducer and 6 mm depth scanhead. All pro-
cedures were carried out according to UK Home Office
regulations.
Quantification of renal cysts
Kidneys were removed from control mice at 12 months
of age, fixed in 10% neutral buffered formalin and
bisected before processing and paraffin embedding. Six
4 μm sections (taken at a 100 μm intervals) were cut
through each kidney and stained with hematoxylin and
eosin. Renal cysts were identified by the presence of a
cuboidal epithelial lining and those with a diameter
above 50 μm were scored as positive. The average num-
ber of cysts per section for each animal was calculated.
Immunohistochemistry
Formalin fixed, paraffin embedded sections were dewaxed
and rehydrated before antigen retrieval by microwaving in
citrate buffer pH 6. Sections were incubated overnight at
4°C with rabbit anti-fumarase (Autogen Bioclear, Calne,
UK) and stained using the EnVision kit (Dako, Glostrup,
Denmark), according to the manufacturer’s instructions.
Detection of Cre-mediated recombination
Ten μm cryosections were cut from snap frozen kidneys
and β-galactosidase activity was measured using X-gal
substrate following a standard procedure (IHC World,
Woodstock, MD, USA).
Metabolomic extraction of mouse urine
Urine was collected and immediately processed for
deproteinization by dilution 1:3 with water and then 1:3
with acetonitrile (by volume). The suspension was then
vortexed and immediately centrifuged at 16,000 g for 15 -
minutes at 0°C. The transparent supernatant was then
submitted to liquid chromatography-mass spectrometry
(LC-MS) metabolomic analysis.
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Metabolomic extraction of cells
A total of 5 × 105 cells were plated onto 6-well plates
and cultured in standard medium for 24 hours. For the
intracellular metabolomic analysis, cells were quickly
washed three times with PBS to remove contaminations
from the metabolites in the media. The PBS was aspi-
rated and cells were lysed by adding a pre-cooled extrac-
tion solution (ES) composed of 50% methanol and 30%
acetonitrile in water. Cell number was counted in a par-
allel control dish, and cells were lysed in 1 ml of ES per
2 × 106 cells. The lysates were vortexed for 5 minutes at
4°C and immediately centrifuged at 16,000 g for 15 -
minutes at 0°C. The supernatants were collected and an-
alyzed by LC-MS. For the metabolomic extraction of
spent media, the media was diluted 1:3 with water and
then deproteinized 1:3 with acetonitrile. The supernatant
was then processed as described above. Fresh medium
without cells was incubated in the same experimental
conditions and used as a reference.
Metabolomic extraction of mouse kidneys
Ten mg of freshly excised mouse kidneys were lysed in
250 μL of a 50% methanol and 30% acetonitrile aqueous
solution using Precellys 24 lysing tubes (tissue homogen-
izing CKMix - KT03961-1-009.2; Bertin Technologies,
Montigny-le-Bretonneux, France), following the manu-
facturer’s instructions. The tissue lysate was immediately
centrifuged at 16,000 g for 15 minutes at 0°C. The
supernatant was collected and analyzed by LC-MS.
LC-MS metabolomic analysis
For the LC separation, column A was the ZIC-HILIC
(150 mm × 2.1 mm, internal diameter (id) 5 μm; SeQuant,
Umeå, Sweden) with a guard column (20 mm × 2.1 mm id
5 μm; Hichrom, Reading, UK). Mobile phase A: 0.1% for-
mic acid v/v in water. Mobile phase B: 0.1% formic acid v/v
in acetonitrile. The flow rate was kept at 100 μL/min and
gradient was as follows: 0 minutes 80% of B, 12 minutes
50% of B, 26 minutes 50% of B, 28 minutes 20% of B, 36 -
minutes 20% of B and 37 to 45 minutes 80% of B. Column
B was the ZIC-pHILIC (150 mm × 2.1 mm id 5 μm;
SeQuant) with the guard column (20 mm × 2.1 mm id
5 μm; Hichrom). Mobile phase C: 20 mM ammonia car-
bonate plus 0.1% ammonia hydroxide in water. Mobile
phase D: acetonitrile. The flow rate was kept at 100 μL/min
and gradient as follows: 0 minutes 80% of D, 30 minutes
20% of D, 31 minutes 80% of D and 45 minutes 80% of D.
The Exactive Orbitrap mass spectrometer (Thermo Scien-
tific, Waltham, MA, USA) was operated in a polarity
switching mode.
Quantification of metabolites
Standard compounds were dissolved in water (concen-
tration range of each metabolite between 1 mM and
10 mM) and then further diluted in a 50:50 acetonitrile:
water solution (solution B, concentration between
20 μM and 200 μM). Cells or media extracts (200 μl)
were then mixed with 800 μl of dilution solvent,
containing 0, 4, 20, 100, 300 or 500 μl of stock solution
B. Samples prepared as indicated were analyzed by LC-
MS. The concentration of each metabolite in the extract
was calculated according to a linear regression fit. All
dilution series were performed in triplicate using three
biological replicates.
13C-glutamine and arginine labeling experiments
A total of 5 × 105 cells were plated onto 6-well plates and
cultured in standard medium for 12 hours. The medium
was then replaced by fresh medium supplemented with ei-
ther 2 mM U-13C-glutamine or 0.4 mM U-13C-arginine
for the indicated time.
Bioinformatics processing and statistical analysis of the
metabolomic data
The cells and media data were log2 transformed and the
replicates normalized using quantile normalization. A
multi-factor analysis of variance and multiple test cor-
rection were then used to identify metabolites signifi-
cantly different between experimental groups. Analyses
were performed using Partek Genomics Suite software
(version 6.5 and R version 2.14.0; Partek, St Louis, MO,
USA).
Short hairpin RNA (shRNA) interference of human and
murine ASL
The lentiviral shRNA plasmids against human
(NM_000048) and murine (NM_133768.4) ASL and
the non-targeting control (RHS 4346) were purchased
from Open Biosystems (Thermo Scientific). The shRNA
for human cells was identified as: V3LHS_375513.
The murine shRNA were: V3LMM_425165 and
V3LMM_425167. All the sequences are free to down-
load from the website: http://www.thermoscientificbio.
com/openbiosystems.
The viral supernatant was obtained from the filtered
growth media of the packaging cells HEK293T transfected
with appropriate packaging plasmids and the relevant
shRNA pGIPZ plasmids using calcium phosphate proced-
ure. Next 2 × 105 Fh1−/− and UOK262 cells were plated
onto 6-well plates and infected with the viral supernatant in
the presence of 4 μg/mL polybrene. After 2 days, the
medium was replaced with selection medium containing
4 μg/mL puromycin. Infection efficiency and shRNA
expression were tracked by monitoring the expression
levels of TurboGFP, a fluorescent protein expressed by the
bicistronic pGIPZ vector.
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Determination of expression levels of ASL
mRNA was extracted as previously described [10]. One
μg of mRNA was retro-transcribed into cDNA using the
High Capacity RNA-to-cDNA Kit (Life Technologies,
Carlsbad, CA, USA). For the qPCR reactions, a duplex sys-
tem of FAM-labeled primers for ASL (Hs00902699_m1 and
Mm01197741_m1), VIC-labeled actin (Mm01205647_g1
for mouse) and lamin (Hs01059202_m1 for human) was
used. One μL of TaqMan Fast Gene Expression Master
Mix (Life Technologies); 1 μL of each primers and probes;
and 4 μL of a 1:10 dilution of cDNA in a final volume of 20
μL were used. The primers were designed using the
Applied Biosystems website. qPCR was performed in the
7500 Fast Real-Time PCR System (Life Technologies) using
the TaqMan Fast program and expression levels of the
indicated genes were calculated using the ΔΔCt method by
the appropriate function of the software using actin or
lamin as calibrators.
Treatment with ADI-PEG 20
A total of 1 × 105 cells were plated onto 24-well plates
and counted every 24 hours for 6 consecutive days using
an Innovatis CASY cell counter (Roche, Hague Road, IN,
USA). For arginine deprivation experiments, ADI-PEG
20 (Polaris Group, San Diego, CA, USA) was dissolved
in cell culture media at the indicated concentration and
replenished every 2 days. Clonogenic survival assay was
performed as previously described [10], and 100 Fh1fl/fl
and 600 Fh1−/− cells were plated per well in a 6-well
plate. Twenty-four hours after plating, ADI-PEG 20 was
added to the medium. Every 2 days, for a total of 8 days,
fresh ADI-PEG 20 was added to the culture media. At
the end of the treatment, the medium was replaced with
fresh medium without the drug/vehicle and cells were
left to grow for a further 4 days. The cells were then
fixed by adding ice-cold trichloroacetic acid onto the
plate at the final concentration of 3% for 1 hour at 4°C.
Cells were then washed with water and air-dried. Then,
cells were stained using 0.47% sulforhodamine B (SRB)
for 30 minutes at room temperature. SRB was removed
and cells were washed with 1% acetic acid and air-dried.
Plates were scanned at the resolution of 600 dpi, 24-bit
and saved as TIFF files. Each experiment was performed
in triplicate plates.
Results
In order to study the metabolic alterations and adapta-
tions of FH-deficient tumors in vivo we used a previ-
ously described mouse model with a conditional Fh1
gene deletion, Fh1fl/fl [4]. These mice were crossed to
transgenic mice expressing the Cre recombinase under
the control of a beta-napthoflavone-inducible promoter
Cyp1A (AhCre) and a lox-stop-lox lacZ reporter cassette
within the Rosa26 locus [18] (Additional file 1A). In the
absence of beta-napthoflavone, the AhCre mice stochas-
tically express the Cre transgene in cells within multiple
organs, such as the kidney, liver, heart and bladder
[19,20]. Consistent with this notion, random recombin-
ation events in the absence of the inducer, with conse-
quent generation of Fh1-deficient cells, were detected by
tail genotyping and by lacZ expression in kidneys of
AhCre and LacZ positive Fh1fl/fl mice, indicated there-
after as AhCreFh1fl/fl (Additional file 1B and C). Import-
antly, the stochastic loss of Fh1 in these mice resulted in
the early formation of renal cysts, as identified by ultra-
sound scanning of AhCreFh1fl/fl mice from the age of 6 -
months (Figure 1A). Post mortem analyses of 1-year-old
AhCreFh1fl/fl mice revealed the presence of multiple
macroscopic renal cysts (Figure 1B and Additional file 1D).
Immunohistological analysis of AhCreFh1fl/fl kidneys con-
firmed the loss of Fh1 expression in the cystic regions
(Additional file 1E).
It is noteworthy that, despite the likeliness of multiple
stochastic events of gene deletion in these mice, the only
observed hyperplasia was in the kidney. Together with
the fact that FH loss-of-function is associated with renal
cancer, these observations indicate that kidney cells may
better survive the loss of the TCA cycle enzyme FH.
Therefore, in order to investigate the metabolic signa-
ture associated with the loss of Fh1 in these mice, the
urine of AhCreFh1fl/fl mice and littermate controls were
collected and analyzed by LC-MS. To increase the statis-
tical robustness of this analysis, urines were collected on
3 separate days. The principal component analysis
(PCA) of the metabolomic data revealed a clear separ-
ation between the AhCreFh1fl/fl and the Fh1-proficient
mice (Figure 1C). Importantly, the absence of metabolic
sub-clustering between the Fh1+/+ and AhCreFh1fl/+ sug-
gests that a monoallelic loss of Fh1 is not sufficient to
generate a metabolic signature (Figure 1C), in line with
the fact that no renal cysts were detected in Fh1 hetero-
zygous mice (not shown). The metabolites that consist-
ently contributed to the urine metabolic signature of
AhCreFh1fl/fl mice were urobilin, S-(2-succinyl)cysteine
(2SC), fumarate and argininosuccinate (Figure 1D). Con-
sidering the robustness of the metabolic signature, these
metabolites may be considered biomarkers for HLRCC
patients. Furthermore, the presence of urobilin (the
urine form of bilirubin) in the urine of mice with Fh1-
deficient cysts strongly supports our previous report that
heme degradation is upregulated in FH-deficient tumors
[10]. 2SC formation is likely due to cysteine addition to
fumarate, as was previously reported to occur on pro-
teins [8,21]. The presence of fumarate in the urine is not
unexpected considering the high levels of fumarate
detected in Fh1-deficient cells and tumors [4,5,10], but
this is the first report which demonstrates the potential
use of urine fumarate as a biomarker for early detection
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of renal cancer formation in HLRCC patients. The pres-
ence of high levels of argininosuccinate in the urine is
somewhat surprising as this is a urea cycle metabolite.
Nevertheless, like fumarate, argininosuccinate levels are
higher in the Fh1-deficient cystic region of the kidney,
indicating that the cysts are the source of these metabo-
lites (Figure 1E).
In order to test whether this could be extended to
HLRCC, the metabolic profile of spent media of the
patient-derived FH-deficient renal cancer cell line UOK262
[22], indicated hereafter as UOK, was compared to FH-
reconstituted UOK cells (UOKpFH) [10]. The PCA
revealed a distinct metabolic signature of UOK cells when
compared to UOKpFH (Figure 2A). Importantly, in
agreement with the metabolic signature of AhCreFh1fl/fl
mouse urine, 2SC, fumarate and argininosuccinate were the
most increased metabolites (Figure 2B). Fumarate and
argininosuccinate were also abundantly present in the
media of the previously described [10] Fh1−/− mouse
epithelial kidney cells (Figure 2C) and also reached high
intracellular levels in both human and mouse FH-deficient
cell lines (Figure 2D).
Next we investigated the possible mechanisms of
argininosuccinate accumulation in FH-deficient cells.
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Figure 1 Identification of urine biomarkers in AhCreFh1fl/fl mice. (A) Representative images from the ultrasound scanning of the kidneys of
AhCreFh1fl/fl mice. Arrows indicate the cysts. (B) Quantification of cyst number in kidney sections from 1-year-old AhCreFh1fl/fl mice performed by
manual counting. Cysts with an average diameter above 50 μm were counted. (C) Principal component analysis (PCA) of the LC-MS urine
metabolomic data obtained from mice with the indicated genotype. (D) Sigmoidal plot representation of the ratio of urinary metabolites based
on the comparison between AhCreFh1fl/fl and Fh1fl/fl mice. Metabolites of interest are indicated. (E) LC-MS analyses of argininosuccinate and
fumarate in kidney samples of AhCreFh1fl/fl and Fh1fl/fl mice sectioned as indicated in the figure. LC-MS, liquid chromatography-mass
spectrometry; PCA, principal component analysis.
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Argininosuccinate is a urea cycle intermediate synthesized
by argininosuccinate synthetase (ASS) from citrulline and
aspartate, and subsequently converted to fumarate and
arginine by ASL (Additional file 2A). Interestingly,
argininosuccinate aciduria is observed in patients deficient
in ASL. Therefore, it is plausible that an increase in
aspartate- and citrulline-derived argininosuccinate is a con-
sequence of ASL inhibition by high levels of fumarate in
FH-deficient cells. However, cells were maintained in
DMEM, which does not contain aspartate and no net up-
take of the small amount of aspartate from the serum was
detected by the described above extracellular metabolomic
analysis (not shown). Therefore, the only source of aspar-
tate in these cells is the TCA cycle (Additional file 2A).
Since glutamine is the major carbon source of TCA cycle
metabolites in these cells [10] (Additional file 3), efficient
production of aspartate would normally require functional
FH (Additional file 2A). Interestingly, however, it was
recently demonstrated that glutamine-derived TCA cycle
metabolites can be formed by reductive carboxylation of
AKG in respiration-deficient cells [12,15]. Therefore, to
test the possibility that aspartate and subsequently
argininosuccinate are produced via this pathway in FH-
deficient cells, we incubated cells with uniformly-
labeled U-13C-glutamine and traced the heavy carbons
(13C) incorporation into intracellular metabolites
(isotopologues) by LC-MS (Additional file 2B, for a
schematic representation of the labeling pattern).
Unexpectedly, in both human and mouse FH-deficient
cells the steady-state levels of aspartate were decreased,
and more importantly aspartate was mostly unlabeled
(Additional file 3). In sharp contrast, argininosuccinate
was quickly labeled with glutamine-derived carbons
(Additional file 3), but unlike the expected contribution of
three 13C from glutamine via aspartate (Additional file 2B),
argininosuccinate major isotopologue was labeled on
four glutamine-derived 13C with a mass shift of four
Daltons (13C4) (Figure 3A). This result suggests that
argininosuccinate is not produced from citrulline and
aspartate in FH-deficient cells but rather from arginine and
fumarate (Figure 3B). This surprising observation may be a
consequence of either enzymatic or non-enzymatic nu-
cleophilic attack of arginine on the electrophilic double
bond of fumarate (Michael addition). When fumarate and
arginine were mixed together in physiological buffer, no
formation of argininosuccinate was detected (Figure 3C).
However, when dialyzed cell extracts from mouse
kidney epithelia Fh1−/− cells were added to the reac-
tion, a substantial production of argininosuccinate was
observed. This reaction was blocked when the protein ex-
tract was heat-inactivated (HI) (Figure 3C). These results
suggest that argininosuccinate production in vitro is enzy-
matically catalyzed.
To test whether ASL is the enzyme required for the
formation of argininosuccinate in vitro, cells were
infected with a lentivirus encoding either short hairpin
RNAs targeting ASL or non-targeting control shRNA
(Figure 4A). When protein lysates from these cells were
used as an enzymatic source for the in vitro reaction, it was
clearly demonstrated that the silencing of ASL drastically
Figure 2 Metabolic fingerprint of FH-deficient cell lines. (A) PCA and (B) sigmoidal plot of the metabolomic data from growth media of the
indicated cell lines. Results were obtained from nine independent cultures. UOK cells present a distinct metabolic signature compared to their
FH-proficient counterpart, UOKpFH. (C) Extracellular and (D) intracellular fumarate and argininosuccinate levels in the indicated cell lines. Results
were obtained from three independent cultures and represented as average ± SEM. PCA, principal component analysis; SEM, standard error of
the mean; UOK, UOK262.
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reduced the in vitro production of argininosuccinate
(Figure 3D). Overall, these results suggest that in the pres-
ence of excess fumarate, ASL is operating in reverse gener-
ating argininosuccinate from fumarate and arginine.
To validate this hypothesis, cells were cultured in the
presence of U-13C-arginine and the isotopologue
distribution of argininosuccinate was assessed. If the
urea cycle is operating in the forward direction produ-
cing argininosuccinate from citrulline and aspartate,
argininosuccinate would be labeled on five arginine-derived
13C (Additional file 4). However, if ASL is indeed working
in reverse in these cells, argininosuccinate would be labeled
on six arginine-derived 13C, due to the direct binding of un-
labeled fumarate to labeled arginine (Additional file 4B).
After 24 hours of incubation with U-13C-arginine, argi-
ninosuccinate was predominantly detected by mass-
spectrometry as the 13C6 isotopologue (Figure 4B and C;
NTC). In addition, only a very small amount of 13C-argin-
ine-derived 13C5 ornithine and no
13C5 citrulline were
detected (Additional file 4C). Finally, the silencing of ASL
in FH-deficient cells (Figure 4A) caused a reduction in the
steady-state levels of argininosuccinate, concomitant with a
reduction in the production of the 13C6 argininosuccinate
isotopologue from U-13C-arginine (Figure 4B and C;
compare shAsl to NTC). Altogether, these results clearly
demonstrate that FH-deficient cells use exogenous arginine
and intracellular fumarate to form argininosuccinate in a
reversed ASL reaction (Figure 4D).
In order to further investigate the biological relevance
of this novel biochemical adaptation mechanism, the
biosynthesis of argininosuccinate was pharmacologically
inhibited by depriving cells of arginine using ADI-PEG
20. This recombinant enzyme converts arginine into
equimolar amounts of citrulline and ammonia. As
expected, this enzyme rapidly converted medium argin-
ine into citrulline (Figure 5A), caused a substantial drop
of intracellular levels and secreted argininosuccinate in
FH-deficient cells (Figure 5B). In order to investigate the
Figure 3 Argininosuccinate is produced from arginine and fumarate. (A) Isotopologue distribution analysis of intracellular metabolites after
incubation with U-13C-glutamine for 24 hours. (B) In light of the isotopologues distribution (13C4) of glutamine-derived
13C-labeled
argininosuccinate in FH-deficient cells (panel A), this scheme represents the most likely biochemical pathway that links TCA cycle metabolites in
FH-deficient cells to the urea cycle and to argininosuccinate production. Arginine and fumarate were mixed in a physiological buffer in the
presence or absence of protein lysates from (C) Fh1−/− cells or (D) Fh1−/− cells in which ASL expression was silenced. The formation of
argininosuccinate is enzymatic and requires ASL. Where indicated, the cell extracts were heat inactivated (HI) prior to the in vitro reaction. Results
were obtained from three independent experiments and expressed as average ± SEM. ASL, argininosuccinate lyase; FH, fumarate hydratase; HI,
heat inactivated; SEM, standard error of the mean.
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effects of arginine deprivation, cells were cultured for 8 days
with ADI-PEG 20 and a colony survival assay was
performed. ADI-PEG 20 caused a measurable change in
colony (cell) survival and it also affected colony size of both
human and mouse FH-deficient cells (Figure 5C); indicating
that these cells are auxotrophic for arginine, and that argin-
ine deprivation affects both cell survival and proliferation.
Discussion
The unexpected finding that mutations in the TCA cycle
enzymes succinate dehydrogenase (SDH) [23] and FH
[24], predispose to cancer, potently rekindled the field of
cancer metabolism and promoted investigations of the
link between aberrant metabolism and cancer formation.
It is remarkable that, despite the fact that FH and SDH
are part of the same biochemical pathway, their loss of
function leads to different spectra of tumors [1]. In line
with this, despite a multi-organ stochastic Fh1 loss in
the AhCreFh1fl/fl mice, the only observed phenotype was
the development of renal cysts. We hypothesized that by
excreting accumulated metabolites, kidney cells may
better tolerate FH deficiency and would therefore enable
fumarate to exert its onco-metabolic activity via the
stabilization of the transcription factors HIF and Nrf2,
and by promoting epigenetic changes via the inhibition
of AKG-dependent dioxygenases [1].
Metabolomic analyses revealed that Fh1-deficient mice
and cells accumulate and excrete significant amounts of
Figure 4 Argininosuccinate is produced by the reverse activity of the urea cycle enzyme ASL. (A) mRNA expression levels of ASL after
acute infection of the indicated cell lines with shRNAs against human (shASL) or mouse (shAsl) ASL. Values are normalized to cells infected with
the control plasmid. Argininosuccinate production is decreased in ASL-silenced (B) human or (C) mouse cells. Cells were incubated with
U-13C-arginine for 24 hours and the isotopologue distribution of argininosuccinate was analyzed by LC-MS. (D) Schematic representation of
the fate of arginine in FH-deficient cells. Orange arrows indicate the major metabolic flux from arginine; light yellow arrow indicates low
metabolic flux, gray arrows indicate undetectable metabolic flux; and dark gray arrow indicates the crosstalk between the TCA cycle and the
urea cycle. All the results were obtained from three independent cultures and expressed as average ± SEM. ASL, argininosuccinate lyase; FH,
fumarate hydratase; LC-MS, liquid chromatography-mass spectrometry; NTC, non-targeting control; SEM, standard error of the mean; shRNA,
short hairpin RNA; TCA, tricarboxylic acid.
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fumarate and fumarate-related metabolites, among which,
argininosuccinate predominated. Since argininosuccinate
accumulation was consistently elevated in our studies, we
propose that it may be a robust metabolic urine biomarker
for the early detection of FH-associated renal cancer.
Argininosuccinate is normally produced in the urea cycle
from citrulline and aspartate, and is further converted into
fumarate and arginine. Of note, this process is particularly
important in the kidneys, since these organs help to main-
tain arginine homeostasis by producing arginine from
dietary citrulline and releasing it to the blood stream [25].
In this work, we have shown that in the presence of excess
fumarate in FH-deficient cells, this reaction is reverted and
argininosuccinate is subsequently produced from fumarate
and arginine. We have demonstrated that the urea cycle in
these cells does operate in the forward direction to
synthesize arginine and instead FH-deficient kidney cancers
employ exogenous arginine to produce argininosuccinate.
In addition, since ASL has been found recently to be
required for systemic nitric oxide biosynthesis [26], the
effects of fumarate on the urea cycle may extend to nitric
oxide metabolism as well.
The secretion of fumarate appears to be the predomin-
ant strategy for FH-deficient cells to sustain viable, even
though strikingly high, intracellular levels of fumarate.
Nevertheless, we propose that ASL reversal partially
contributes to fumarate detoxification and could have a
role in the survival of FH-deficient cells. In fact, when
cells were deprived of arginine using the recombinant en-
zyme, ADI-PEG 20, intracellular levels of argininosuccinate
declined dramatically with severe consequences on cell pro-
liferation. Although the genetic ablation of ASL has not
been specifically investigated in the current study, it is
tempting to speculate that other metabolic pathways might
be exploited upon the loss of function of ASL to avoid fu-
marate accumulation.
Conclusion
Our results highlight the complex and convoluted meta-
bolic changes that occur after the loss of FH. In particu-
lar, these results suggest that FH-deficient cells have
evolved mechanisms to compensate for the persistent
intracellular accumulation of fumarate which would be
otherwise toxic and would impair cellular proliferation.
Figure 5 Arginine depletion by ADI-PEG 20 reduces argininosuccinate and inhibits cellular proliferation in FH-deficient cells. (A)
Arginine levels determined in the media of the indicated cell lines after the incubation for 4 hours with 125 ng/mL ADI-PEG 20. (B) Excreted and
intracellular levels of argininosuccinate after treatment with ADI-PEG 20, as in (A), were detected by LC-MS. (C) Representative images of a colony
survival assay after treatment with either 125 ng/mL (mouse cells) or 50 ng/mL (human cells) ADI-PEG 20 for 8 days. The media was replaced and
cells were left to grow for a further 4 days before fixation and staining. All the results were obtained from three independent cultures and
expressed as average ± SEM. FH, fumarate hydratase; LC-MS, liquid chromatography-mass spectrometry; SEM, standard error of the mean.
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In addition, our approach provides a novel and practical
way to screen for metabolic biomarkers in HLRCC and
other FH-related kidney cancer patients. Finally, the ob-
servation that, unlike normal kidney epithelial cells, FH-
deficient kidney cancer cells are auxotrophic for arginine
provides potential new therapeutic interventions for
these cancers.
Additional files
Additional file 1: Characterization of AhCreFh1fl/fl mice. (A)
Schematic representation of the Fh1 allele in Fh1fl/fl mice, and the
construct used for the generation of AhCre and the LacZ reporter at the
Rosa26 locus. (B) Tail clipping genotyping of AhCreFh1fl/fl mice. The
putative genotypes are indicated on the left, based on the expected size
of the genomic PCR amplification products. Fh1+/+ = 230 bp, Fh1flfl = 470
bp and Fh1-/-= 380 bp. (C) Representative images of the lacZ staining
performed on cryosections of dissected kidneys of the indicated mice.
The bar indicates 200 μm. (D) Representative image (left) and relative
hematoxylin and eosin staining (right) of a dissected kidney from
AhCreFh1fl/fl mice. The arrow on the left panel indicates a macrocyst. The
bar on the right panel indicates 200 μm. (E) Immunohistochemistry for
Fh1 performed on a kidney section of the indicated mouse strains. The
bar indicates 200 μm.
Additional file 2: Schematic representation of the metabolic
crosstalk between the urea cycle and the TCA cycle. (A) In normal
conditions, aspartate reacts with citrulline to produce argininosuccinate, a
reaction catalyzed by ASS. Argininosuccinate is then converted into
arginine and fumarate by ASL. (B) Schematic representation of a putative
labeling of argininosuccinate in FH-deficient cells where the reductive
carboxylation of AKG will generate labeled aspartate (13C3). Note that this
representation does not take into account N-N chemical bound. AKG,
alpha-ketoglutarate; ASL, argininosuccinate lyase; ASS, argininosuccinate
synthetase; FH, fumarate hydratase; TCA, tricarboxylic acid.
Additional file 3: Isotopologue distribution of TCA cycle
metabolites after incubation with U-13C-glutamine. (A) Mouse and
(B) human FH-deficient or proficient cell lines were incubated for the
indicated time with 2 mmol/L U-13C-glutamine, and both the spent
media and the intracellular metabolites were analyzed by LC-MS. The
isotopologue composition is indicated in the legend and presented as
peak area. FH, fumarate hydratase; LC-MS, liquid chromatography-mass
spectrometry; TCA, tricarboxylic acid.
Additional file 4: Schematic representation of the hypothetic
labeling profiles of argininosuccinate from U-13C-arginine-labelling
experiments. After the incubation with labeled arginine,
argininosuccinate can be labeled either as (A) 13C5 due to a fully
functional urea cycle, or (B) as 13C6 if arginine is converted directly into
argininosuccinate by the reversed activity of ASL. (C) Citrulline and
ornithine detection by LC-MS in cells incubated with U-13C-arginine. ASL,
argininosuccinate lyase; LC-MS, liquid chromatography-mass
spectrometry.
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